The US Food and Drug Administration (FDA) has cleared the next-generation NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) device for patients with treatment-resistant major depressive disorder (MDD), the company has announced.
…
“We have widespread insurance reimbursement from most commercial and government health plans, and a next-generation NeuroStar Advanced Therapy that uses proprietary technology and a 19-minute treatment that allows patients to get in and out before work or during their lunch hour,” NeuroStar President and CEO Chris Thatcher said in the release.
…
Research has shown that TMS can provide lasting relief of antidepressant-resistant MDD and improved quality of life for patients.
To read the complete Medscape article, click here
